Irritable Bowel Syndrome – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Irritable Bowel Syndrome – Pipeline Review, H1 2017’, provides an overview of the Irritable Bowel Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome

The report reviews pipeline therapeutics for Irritable Bowel Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Irritable Bowel Syndrome therapeutics and enlists all their major and minor projects

The report assesses Irritable Bowel Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4D Pharma PLC

A. Menarini Industrie Farmaceutiche Riunite Srl

Alfa Wassermann SpA

Allergan Plc

Ardelyx Inc

Astellas Pharma Inc

CJ HealthCare Corp

ConSynance Therapeutics Inc

Cosmo Pharmaceuticals NV

Dong-A ST Co., Ltd.

Eisai Co Ltd

Enterome Bioscience SA

GlaxoSmithKline Plc

Innovative Med Concepts LLC

Ironwood Pharmaceuticals Inc

Kissei Pharmaceutical Co Ltd

Lexicon Pharmaceuticals Inc

Napo Pharmaceuticals Inc

Pfizer Inc

RaQualia Pharma Inc

RedHill Biopharma Ltd

SK Biopharmaceuticals Co Ltd

Sumitomo Dainippon Pharma Co Ltd

Synergy Pharmaceuticals Inc

Synthetic Biologics Inc

Vitality Biopharma Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Irritable Bowel Syndrome - Overview 8

Irritable Bowel Syndrome - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 16

Irritable Bowel Syndrome - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 27

4D Pharma PLC 27

A. Menarini Industrie Farmaceutiche Riunite Srl 27

Alfa Wassermann SpA 28

Allergan Plc 28

Ardelyx Inc 29

Astellas Pharma Inc 29

CJ HealthCare Corp 30

ConSynance Therapeutics Inc 30

Cosmo Pharmaceuticals NV 31

Dong-A ST Co., Ltd. 31

Eisai Co Ltd 32

Enterome Bioscience SA 32

GlaxoSmithKline Plc 33

Innovative Med Concepts LLC 33

Ironwood Pharmaceuticals Inc 34

Kissei Pharmaceutical Co Ltd 35

Lexicon Pharmaceuticals Inc 35

Napo Pharmaceuticals Inc 36

Pfizer Inc 36

RaQualia Pharma Inc 37

RedHill Biopharma Ltd 37

SK Biopharmaceuticals Co Ltd 38

Sumitomo Dainippon Pharma Co Ltd 38

Synergy Pharmaceuticals Inc 39

Synthetic Biologics Inc 39

Vitality Biopharma Inc 40

Irritable Bowel Syndrome - Drug Profiles 41

(celecoxib + famciclovir) - Drug Profile 41

ASP-7147 - Drug Profile 43

bedoradrine sulfate - Drug Profile 44

Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile 47

Biologic for Irritable Bowel Syndrome with Diarrhea - Drug Profile 48

Blautix - Drug Profile 49

Canchew Plus - Drug Profile 51

CJ-14199 - Drug Profile 52

crofelemer DR - Drug Profile 53

CSTI-300 - Drug Profile 57

DA-6886 - Drug Profile 58

Drugs for Irritable Bowel Syndrome with Diarrhea - Drug Profile 59

DSP-6952 - Drug Profile 60

E-2508 - Drug Profile 61

EB-420 - Drug Profile 62

GSK-3179106 - Drug Profile 63

ibodutant - Drug Profile 64

linaclotide - Drug Profile 65

linaclotide DR1 - Drug Profile 73

linaclotide DR2 - Drug Profile 74

lovastatin - Drug Profile 75

LT-4006 - Drug Profile 79

LX-1033 - Drug Profile 80

ondansetron hydrochloride CR - Drug Profile 82

ORP-101 - Drug Profile 88

PBF-677 - Drug Profile 89

plecanatide - Drug Profile 90

PR-38 - Drug Profile 99

pregabalin - Drug Profile 100

relenopride hydrochloride - Drug Profile 105

rifamycin CR - Drug Profile 107

rifaximin - Drug Profile 110

RQ-00202730 - Drug Profile 114

RQ-00310941 - Drug Profile 115

Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 116

solabegron hydrochloride - Drug Profile 117

tenapanor hydrochloride - Drug Profile 120

VB-210 - Drug Profile 125

Irritable Bowel Syndrome - Dormant Projects 126

Irritable Bowel Syndrome - Discontinued Products 129

Irritable Bowel Syndrome - Product Development Milestones 130

Featured News & Press Releases 130

Appendix 145

Methodology 145

Coverage 145

Secondary Research 145

Primary Research 145

Expert Panel Validation 145

Contact Us 145

Disclaimer 146

List of Tables

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Irritable Bowel Syndrome – Pipeline by 4D Pharma PLC, H1 2017

Irritable Bowel Syndrome – Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2017

Irritable Bowel Syndrome – Pipeline by Alfa Wassermann SpA, H1 2017

Irritable Bowel Syndrome – Pipeline by Allergan Plc, H1 2017

Irritable Bowel Syndrome – Pipeline by Ardelyx Inc, H1 2017

Irritable Bowel Syndrome – Pipeline by Astellas Pharma Inc, H1 2017

Irritable Bowel Syndrome – Pipeline by CJ HealthCare Corp, H1 2017

Irritable Bowel Syndrome – Pipeline by ConSynance Therapeutics Inc, H1 2017

Irritable Bowel Syndrome – Pipeline by Cosmo Pharmaceuticals NV, H1 2017

Irritable Bowel Syndrome – Pipeline by Dong-A ST Co., Ltd., H1 2017

Irritable Bowel Syndrome – Pipeline by Eisai Co Ltd, H1 2017

Irritable Bowel Syndrome – Pipeline by Enterome Bioscience SA, H1 2017

Irritable Bowel Syndrome – Pipeline by GlaxoSmithKline Plc, H1 2017

Irritable Bowel Syndrome – Pipeline by Innovative Med Concepts LLC, H1 2017

Irritable Bowel Syndrome – Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Irritable Bowel Syndrome – Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017

Irritable Bowel Syndrome – Pipeline by Lexicon Pharmaceuticals Inc, H1 2017

Irritable Bowel Syndrome – Pipeline by Napo Pharmaceuticals Inc, H1 2017

Irritable Bowel Syndrome – Pipeline by Pfizer Inc, H1 2017

Irritable Bowel Syndrome – Pipeline by RaQualia Pharma Inc, H1 2017

Irritable Bowel Syndrome – Pipeline by RedHill Biopharma Ltd, H1 2017

Irritable Bowel Syndrome – Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Irritable Bowel Syndrome – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Irritable Bowel Syndrome – Pipeline by Synergy Pharmaceuticals Inc, H1 2017

Irritable Bowel Syndrome – Pipeline by Synthetic Biologics Inc, H1 2017

Irritable Bowel Syndrome – Pipeline by Vitality Biopharma Inc, H1 2017

Irritable Bowel Syndrome – Dormant Projects, H1 2017

Irritable Bowel Syndrome – Dormant Projects, H1 2017 (Contd..1), H1 2017

Irritable Bowel Syndrome – Dormant Projects, H1 2017 (Contd..2), H1 2017

Irritable Bowel Syndrome – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Irritable Bowel Syndrome, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports